Impact of previous metronidazole exposure on metronidazole-based second-line quadruple therapy for Helicobacter pylori infection

Article information

Korean J Intern Med. 2020;35(5):1094-1103

Publication date (electronic) : 2020 July 31

doi : https://doi.org/10.3904/kjim.2020.174

Gil Ho Lee, Kee Myung Lee, Sung Jae Shin, Joon Koo Kang, Choong-Kyun Noh, Jin Hong Kim, Sun Gyo Lim

Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea

Correspondence to Sun Gyo Lim, M.D. Department of Gastroenterology, Ajou University School of Medicine, 164 World cup-ro, Yeongtong-gu, Suwon 16499, Korea Tel: +82-31-219-6939 Fax: +82-31-219-5999 E-mail: mdlsk75@ajou.ac.kr

Received 2020 April 24; Revised 2020 June 13; Accepted 2020 July 9.

Abstract

INTRODUCTION

Helicobacter pylori is a gram-negative, microaerophilic bacterium that resides in the stomach and is a major risk factor for gastric neoplastic and peptic ulcer diseases [1,2]. According to epidemiological and experimental studies, the prevalence of H. pylori-related diseases has been decreasing owing to the aggressive eradication therapy for H. pylori infection [3]. However, recent studies have demonstrated that the success rates of H. pylori eradication have been gradually decreasing [4-6]. Among the important factors affecting the failure of H. pylori eradication, antibiotic resistance has been consistently reported to be a major cause of treatment failure [7,8].

In Korea, clarithromycin (CAM)-based triple therapy has been recommended as a first-line eradication therapy. A meta-analysis of 104 studies on the Korean standard CAM-based triple therapy and a Korean nationwide multicenter study showed that the success rate of standard triple therapy significantly reduced from 1998 to 2013 [6,9,10].

Although an antimicrobial susceptibility test is the gold standard for establishing antibiotic resistance, obtaining the equipment for its performance and applying it to clinical practice is usually difficult. Recently, dual priming oligonucleotide-based multiplex polymerase chain reaction was developed to identify CAM resistance and help predict the failure of CAM-based H. pylori eradication therapy [11,12]. However, a reliable test to identify metronidazole (MET) resistance does not exist. Therefore, clinical information that can predict antibiotic resistance and eradication failure needs to be utilized to provide an individualized treatment strategy for H. pylori infection. Previously, we demonstrated that the failure rate of CAMbased first-line eradication therapy was significantly increased in patients with a history of CAM and macrolide use [13]. However, the relationship between past MET use and H. pylori eradication failure using a quadruple regimen that includes MET has not been determined.

Therefore, we aimed to investigate the relationship between past use of MET and the failure of MET-based second-line quadruple therapy for H. pylori infection. This knowledge would further the ability to provide an individualized treatment strategy for patients with H. pylori infection.

METHODS

Study population

This retrospective cohort study evaluated whether a previous use of MET affected the failure of second-line H. pylori eradication therapy. The clinical research database used in this study consists of clinical, prescriptive, laboratory, and administrative data from the records of approximately 2.3 million people observed at a South Korean tertiary teaching hospital (Ajou University Hospital) from January 1998 to March 2016.

The data search and selection process is shown in Fig. 1. All patients over 20 years of age who were diagnosed with H. pylori infection between January 1998 and March 2016 were included in the study. H. pylori infection was defined as a positive result in a rapid urease test performed by esophagogastroduodenoscopy or in a pathologic analysis of a biopsy specimen. Some patients tested positive in the follow-up urea breath test (UBT; Korea Otsuka Pharmaceutical, Seoul, Korea) 4 to 12 weeks after undergoing first-line 7-day standard triple therapy consisting of 1 g twice a day amoxicillin (AMX), 500 mg twice a day CAM, and one of the proton pump inhibitors (PPIs; 40 mg pantoprazole, 30 mg lansoprazole, 20 mg esomeprazole, 20 mg rabeprazole; twice daily). Among then, the patients who underwent the 7-day MET-based second-line quadruple therapy (one of the aforementioned PPIs twice daily, 300 mg tripotassium dicitrate bismuthate and 500 mg tetracycline four times daily, and 500 mg MET thrice daily) and underwent follow-up UBT at 4 to 12 weeks were finally included in this study.

Figure 1.

Study protocol sheet. H. pylori, Helicobacter pylori; UBT, urea breath test.

The enrolled patients were divided into two groups: patients with a history of MET medication and those without a history of MET medication. The exclusion criteria were age < 20 years, the absence of a follow-up UBT at 4 to 12 weeks after therapy, or any history of gastric surgery. This study protocol was approved by the Institutional Review Board of Ajou University Hospital (AJIRB-MED-MDB-17-379), and the requirement of informed consent was waived owing to the anonymous nature of the retrospective cohort data.

RESULTS

Baseline characteristics

The demographic and clinical characteristics and the results of the univariate analysis are presented in Table 1. A total of 612 patients underwent second-line eradication therapy with a MET-based quadruple regimen. Of them, 179 (29.2%) were over 60 years old, and 337 (55.1%) were male. The rates of the enrolled patients’ comorbidities were: diabetes in 40 patients (6.5%), chronic hepatitis in six (1.0%), liver cirrhosis in five (0.8%), and ESRD in six (1.0%). A total of 239 patients (39.1%) had a gastroduodenal ulcer, and 31 (5.1%) had a history of previous MET use. Overall, the H. pylori eradication rate of MET-based second-line quadruple therapy was 91.5% (560 of 612), while that in patients with a history of MET use was 77.4% (24 of 31).

Table 1.

Baseline characteristics of the patients

Relationship between the failure rate of second-line H. pylori eradication therapy and various clinical factors

The failure rate of eradication therapy was not significantly correlated with clinical factors, such as age, sex, underlying disease (diabetes mellitus, chronic hepatitis, liver cirrhosis, ESRD), or the presence of a gastroduodenal ulcer. The failure rate of eradication therapy was significantly higher in patients with previous MET use than in patients without a history of MET use (22.6% vs. 7.7%, p = 0.011). Multivariable binary logistic regression analysis showed that the odds ratio of past MET use for treatment failure was 3.468 (95% confidence interval, 1.391 to 8.649; p = 0.008) (Table 2). Among the 31 patients with a history of MET use, clinical factors, such as sex, reason of MET use, route of MET administration, daily dose of MET, and MET use during operation did not significantly affect the treatment outcome of the 7-day MET-based second-line H. pylori eradication therapy (Table 3).

Table 2.

Multivariable analysis of the relationship between clinical factors and the failure of Helicobacter pylori eradication therapy

Table 3.

Outcomes of 7-day metronidazole-based 2nd line quadruple therapy in patients with a history of metronidazole use according to various clinical factors

Relationship between the failure rate of H. pylori eradication therapy and the duration of MET use

An analysis of the effect of the duration of MET use and the interval between MET use and eradication therapy on eradication failure was performed for 31 patients with a history of MET use. The numbers of patients who had taken MET for ≥ 14 days or for < 14 days were eight and 23, respectively. The failure rates of H. pylori eradication were 50% (4/8) and 13% (3/23) for the two groups, respectively (p = 0.053) (Table 4). As for the effect of the duration of previous MET use, the failure rate of eradication therapy tended to increase in patients with ≥ 14 days of MET use than in those of patients with < 14 days of usage (p = 0.05).

Table 4.

Results of Helicobacter pylori eradication therapy in patients with a history of metronidazole use

DISCUSSION

This retrospective cohort study showed that previous exposure to MET had a significant impact on the failure of MET-based second-line eradication therapy of H. pylori. This study is the first to investigate the relationship between previous MET use and the failure of MET-based H. pylori eradication therapy. Using binary logistic regression analysis for risk assessment, a previous use of MET was identified to be an independent risk factor for the failure of MET-based second-line quadruple therapy. In patients who had a > 14-day history of MET administration, the failure rate of H. pylori eradication was significantly increased. These results agreed with those of a previous study, which revealed that a history of macrolide treatment was closely related to the increased failure rate of CAM-based H. pylori eradication therapy [14].

According to the Maastricht V/Florence Consensus, after PPI-CAM-AMX triple therapy failure, bismuth quadruple therapy (BQT) or fluoroquinolone-containing triple or quadruple therapy are recommended as second-line treatments [15]. In areas of high CAM and MET resistance, BQT is the recommended first-line regimen in cases of H. pylori infection.

If 7-day CAM-based standard triple therapy fails in patients with a history of MET use, the following strategies are available. First, 14-day CAM-based standard triple therapy could be recommended based on the results of the meta-analyses [16-18]. Second, prolongation of MET-based eradication therapy could be considered. A 10- or 14-day MET-based BQT has been reported to improve the success rate of H. pylori eradication [19-22]. However, most of these studies were not performed on the basis of antibiotic susceptibility testing. Therefore, on an individual basis, it is questionable whether the outcomes of 10- or 14-day MET-based second-line quadruple therapy in patients with a history of MET use would be improved, as was observed in patients without a history of MET use. Upon further analysis, among patients who had received 10- or 14-day MET-based BQT in our medical center and whose data were not included in this study, the success rate of H. pylori eradication was lower in patients with a history of MET than that of those who had no such history (81.3% vs 95.2%, p = 0.54). This result showed that prolongation of MET-based second-line quadruple therapy might not improve the success rate of H. pylori eradication therapy in patients who had previously taken MET.

MET is activated via reduction in bacteria to produce nitro-anion radicals and imidazole intermediates, which damage bacterial DNA, thus exhibiting antibacterial activity. To date, MET has been used as a primary antibiotic in the second-line treatment of H. pylori infection. However, MET has a higher possibility of conferring antibiotic resistance than other antibiotics. In Korea, the resistance rates of MET have been reported to be between 35.8% to 56.3% since 2010 [14,23-27].

A previous study reported that diabetes mellitus may be a factor in reducing the eradication rate in second-line BQT [28]. Additionally, female sex [29-33] and the presence of a gastroduodenal ulcer [34-36] are associated with the failure of H. pylori eradication therapy. However, these factors were not significantly associated with the treatment failure of H. pylori infection in this study.

According to the studies that analyzed the results of MET-based quadruple therapy for H. pylori infection, the eradication rates ranged from 74% to 93.6% when this regimen was prescribed as a second-line treatment to patients for whom CAM-based triple eradication therapy failed [14,37-39]. These values are consistent with the results of the current study. Although this study analyzed data of patients who underwent 7-day METbased second-line BQT, recent guidelines on H. pylori eradication therapy recommend 10- or 14-day, rather than 7-day, eradication for H. pylori. Several studies have showed results consistent with these guidelines [27,40].

The results of this study show the importance of determining the history of MET use from patient medical records. Throughout the previous studies, no clinical factor has predicted the failure of MET-based antibacterial treatment as much as the history of MET use. Moreover, MET resistance cannot be predicted by clinically available laboratory tests. For CAM, genetic tests that can determine antibiotic resistance by evaluating a point mutation are available commercially and used in clinical practice [14].

Understanding past antibiotic consumption may be helpful for predicting the outcome and improving the success rate of H. pylori eradication therapy. Therefore, confirming a patient’s past history of antibiotic use before initiating eradication therapy could yield better treatment outcomes than conventional empirical treatment, as recommended in the current guidelines. In addition, the practical difficulty of identifying antibiotic resistance through laboratory testing can be avoided. Although patients may have a history of antibiotic use, antibiotic resistance does not always develop. However, increased antibiotic resistance has been reported in patients with a history of antibiotic use. Antibiotic resistance has also been reported in patients with a history of MET use [41,42]. As there is no reliable test to check for antibiotic resistance to MET for H. pylori, a history of MET use has to be utilized as a significant clinical factor to set a strategy for H. pylori eradication as stated in the Maastricht V/Florence Consensus Report [15].

This study has several limitations. Because the data were analyzed retrospectively, other clinical factors, such as compliance, drinking, and smoking, could not be analyzed. In this study, the drug compliance of the 7-day MET-based second-line quadruple therapy based on the medical records in this study was estimated to be 90%, meaning that drug compliance is not considered to affect the results of this study. The side effects of eradication drugs were shown to be mild for most patients in the medical records, and the overall rate of side effects was conjectured as approximately 5% to 10%. In addition, studies conducted by a single institution, without information regarding the diagnosis or treatment by other hospitals, have limited the participants to those at our center. Therefore, the patient group may not represent the community. Additionally, limiting the patients to those who underwent UBT to determine eradication therapy success may have led to selective bias. However, this decision was made to reduce the disturbances caused by differences in the sensitivity and specificity of various tests used to diagnose H. pylori infection. Because an antibiotic resistance test was not performed, the actual prevalence of antibiotic resistance could not be confirmed.

In conclusion, our study showed that previous MET use was significantly associated with the treatment failure of 7-day MET-based second-line quadruple therapy in H. pylori infection. Therefore, we suggest that any history of MET use must be used to establish a treatment plan for patients who need MET-based therapy for H. pylori eradication. A large-scale prospective study should be performed to evaluate the history of MET use on H. pylori eradication therapy.

KEY MESSAGE

Article information Continued